Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Can integrative biomarker approaches improve prediction of platinum and PARP inhibitor response in ovarian cancer?
Authors
Keywords
Homologous recombination deficiency, Platinum sensitivity, PARP inhibition, Predictive biomarkers, Personalised therapy
Journal
SEMINARS IN CANCER BIOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-02-18
DOI
10.1016/j.semcancer.2021.02.008
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer
- (2020) Adrienne G. Waks et al. ANNALS OF ONCOLOGY
- Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer: ASCO Guideline
- (2020) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial
- (2020) Richard T. Penson et al. JOURNAL OF CLINICAL ONCOLOGY
- The evolutionary history of 2,658 cancers
- (2020) Moritz Gerstung et al. NATURE
- The repertoire of mutational signatures in human cancer
- (2020) Ludmil B. Alexandrov et al. NATURE
- Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma
- (2020) Anne Montfort et al. BRITISH JOURNAL OF CANCER
- Detection of ctDNA from Dried Blood Spots after DNA Size Selection
- (2020) Katrin Heider et al. CLINICAL CHEMISTRY
- Unraveling tumor–immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy
- (2020) Alejandro Jiménez-Sánchez et al. NATURE GENETICS
- Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275
- (2020) Matthew D. Galsky et al. CLINICAL CANCER RESEARCH
- Combined CCNE1 high‐level amplification and overexpression is associated with unfavourable outcome in tubo‐ovarian high‐grade serous carcinoma
- (2020) Angela MY Chan et al. Journal of Pathology Clinical Research
- DNA Damage and Cancer Immunotherapy: A STING in the Tale
- (2020) Timo Reisländer et al. MOLECULAR CELL
- PARP1 inhibitors trigger innate immunity via PARP1 trapping-induced DNA damage response
- (2020) Chiho Kim et al. eLife
- BRCA2 deficiency instigates cGAS-mediated inflammatory signaling and confers sensitivity to tumor necrosis factor-alpha-mediated cytotoxicity
- (2019) Anne Margriet Heijink et al. Nature Communications
- The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches
- (2019) Mirjam Gerwing et al. Nature Reviews Clinical Oncology
- ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†
- (2019) N Colombo et al. ANNALS OF ONCOLOGY
- Olaparib maintenance for first-line treatment of ovarian cancer: will SOLO1 reset the standard of care?
- (2019) Rowan E Miller et al. Future Oncology
- Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
- (2019) Paul A. Cohen et al. GYNECOLOGIC ONCOLOGY
- Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
- (2019) Kathleen N Moore et al. LANCET ONCOLOGY
- Detecting the mutational signature of homologous recombination deficiency in clinical samples
- (2019) Doga C. Gulhan et al. NATURE GENETICS
- PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer
- (2019) Constantia Pantelidou et al. Cancer Discovery
- Liquid biopsy-based comprehensive gene mutation profiling for gynecological cancer using CAncer Personalized Profiling by deep Sequencing
- (2019) Naoyuki Iwahashi et al. Scientific Reports
- Whole-genome sequencing of triple-negative breast cancers in a population-based clinical study
- (2019) Johan Staaf et al. NATURE MEDICINE
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
- (2019) Andrew R Clamp et al. LANCET
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- Enhanced response rate to pegylated liposomal doxorubicin in high grade serous ovarian carcinomas harbouring BRCA1 and BRCA2 aberrations
- (2018) Robert L. Hollis et al. BMC CANCER
- Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality
- (2018) Ewa Gogola et al. CANCER CELL
- Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer
- (2018) Allen W. Zhang et al. CELL
- Analytical Validation of a Hybrid Capture–Based Next-Generation Sequencing Clinical Assay for Genomic Profiling of Cell-Free Circulating Tumor DNA
- (2018) Travis A. Clark et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Biomarker Assessment of HR Deficiency, TumorBRCA1/2Mutations, andCCNE1Copy Number in Ovarian Cancer: Associations with Clinical Outcome Following Platinum Monotherapy
- (2018) Euan A. Stronach et al. MOLECULAR CANCER RESEARCH
- SLFN11 Blocks Stressed Replication Forks Independently of ATR
- (2018) Junko Murai et al. MOLECULAR CELL
- Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells
- (2018) Harveer Dev et al. NATURE CELL BIOLOGY
- Evaluation of homologous recombination deficiency (HRD) status with pathological response to carboplatin +/- veliparib in BrighTNess, a randomized phase 3 study in early stage TNBC.
- (2018) Melinda L. Telli et al. JOURNAL OF CLINICAL ONCOLOGY
- Copy number signatures and mutational processes in ovarian carcinoma
- (2018) Geoff Macintyre et al. NATURE GENETICS
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness
- (2018) Jianfeng Shen et al. CANCER RESEARCH
- Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
- (2018) Marthe M. de Jonge et al. CLINICAL CANCER RESEARCH
- Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials
- (2018) Ignace Vergote et al. LANCET ONCOLOGY
- State-of-the-art strategies for targeting the DNA damage response in cancer
- (2018) Patrick G. Pilié et al. Nature Reviews Clinical Oncology
- DNA damage-induced cell death relies on SLFN11-dependent cleavage of distinct type II tRNAs
- (2018) Manqing Li et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Enhanced detection of circulating tumor DNA by fragment size analysis
- (2018) Florent Mouliere et al. Science Translational Medicine
- BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
- (2018) Kevin K Lin et al. Cancer Discovery
- BRCA1 and RAD51C promoter hypermethylation confer sensitivity to the PARP inhibitor rucaparib in patients with relapsed, platinum-sensitive ovarian carcinoma in ARIEL2 Part 1
- (2017) E.M. Swisher et al. GYNECOLOGIC ONCOLOGY
- Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition
- (2017) Stephanie Lheureux et al. JOURNAL OF CLINICAL ONCOLOGY
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
- (2017) Elizabeth L. Christie et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial
- (2017) Elizabeth M Swisher et al. LANCET ONCOLOGY
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- cGAS surveillance of micronuclei links genome instability to innate immunity
- (2017) Karen J. Mackenzie et al. NATURE
- Mitotic progression following DNA damage enables pattern recognition within micronuclei
- (2017) Shane M. Harding et al. NATURE
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- The impact of replication stress on replication dynamics and DNA damage in vertebrate cells
- (2017) Hervé Técher et al. NATURE REVIEWS GENETICS
- Integrating Clinical and Multiple Omics Data for Prognostic Assessment across Human Cancers
- (2017) Bin Zhu et al. Scientific Reports
- Poor concordance between CA-125 and RECIST at the time of disease progression in patients with platinum-resistant ovarian cancer: analysis of the AURELIA trial
- (2016) K. Lindemann et al. ANNALS OF ONCOLOGY
- Low-grade serous carcinoma of the ovary or peritoneum
- (2016) D. M. Gershenson ANNALS OF ONCOLOGY
- Olaparib monotherapy in patients with advanced relapsed ovarian cancer and a germlineBRCA1/2mutation: a multistudy analysis of response rates and safety
- (2016) U. A. Matulonis et al. ANNALS OF ONCOLOGY
- ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells
- (2016) Aparajitha Vaidyanathan et al. BRITISH JOURNAL OF CANCER
- In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma
- (2016) Mariam M. AlHilli et al. GYNECOLOGIC ONCOLOGY
- An Immunohistochemical Algorithm for Ovarian Carcinoma Typing
- (2016) Martin Köbel et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- RING domain–deficient BRCA1 promotes PARP inhibitor and platinum resistance
- (2016) Yifan Wang et al. JOURNAL OF CLINICAL INVESTIGATION
- New paradigms forBRCA1/BRCA2testing in women with ovarian cancer: results of the Genetic Testing in Epithelial Ovarian Cancer (GTEOC) study
- (2016) Inga Plaskocinska et al. JOURNAL OF MEDICAL GENETICS
- Replication fork stability confers chemoresistance in BRCA-deficient cells
- (2016) Arnab Ray Chaudhuri et al. NATURE
- Landscape of somatic mutations in 560 breast cancer whole-genome sequences
- (2016) Serena Nik-Zainal et al. NATURE
- Replication stress: getting back on track
- (2016) Matteo Berti et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- The "cancer immunogram"
- (2016) C. U. Blank et al. SCIENCE
- Replication stress: getting back on track
- (2016) Matteo Berti et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
- (2016) Junko Murai et al. Oncotarget
- Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
- (2016) Kyle C. Strickland et al. Oncotarget
- Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
- (2016) Christine A. Parkinson et al. PLOS MEDICINE
- A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer
- (2015) M Koti et al. BRITISH JOURNAL OF CANCER
- Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma
- (2015) Steffen Böhm et al. JOURNAL OF CLINICAL ONCOLOGY
- Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT)
- (2015) Donavan T. Cheng et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial
- (2015) Amit M Oza et al. LANCET ONCOLOGY
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes
- (2015) Sally M. Hunter et al. Oncotarget
- Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
- (2015) Roland F. Schwarz et al. PLOS MEDICINE
- The Association between Endometriomas and Ovarian Cancer: Preventive Effect of Inhibiting Ovulation and Menstruation during Reproductive Life
- (2015) Giovanni Grandi et al. Biomed Research International
- Combination therapy with BRAF and MEK inhibitors for melanoma: latest evidence and place in therapy
- (2015) Zeynep Eroglu et al. Therapeutic Advances in Medical Oncology
- Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA
- (2015) Richard B. Lanman et al. PLoS One
- Distinct Patterns of Structural and Numerical Chromosomal Instability Characterize Sporadic Ovarian Cancer
- (2015) Jane Bayani et al. NEOPLASIA
- Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
- (2014) K. A. T. Naipal et al. CLINICAL CANCER RESEARCH
- Mutational signatures: the patterns of somatic mutations hidden in cancer genomes
- (2014) Ludmil B Alexandrov et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Defective removal of ribonucleotides from DNA promotes systemic autoimmunity
- (2014) Claudia Günther et al. JOURNAL OF CLINICAL INVESTIGATION
- Up-regulation of the interferon-related genes inBRCA2knockout epithelial cells
- (2014) Hong Xu et al. JOURNAL OF PATHOLOGY
- Ovarian cancer
- (2014) Gordon C Jayson et al. LANCET
- An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
- (2014) Aaron M Newman et al. NATURE MEDICINE
- Mechanisms underlying mutational signatures in human cancers
- (2014) Thomas Helleday et al. NATURE REVIEWS GENETICS
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA damage and innate immunity: links and trade-offs
- (2014) Georgia Chatzinikolaou et al. TRENDS IN IMMUNOLOGY
- Copy neutral loss of heterozygosity is more frequent in older ovarian cancer patients
- (2013) Brent S. Pedersen et al. GENES CHROMOSOMES & CANCER
- The prognostic significance of pre- and post-treatment CA-125 in grade 1 serous ovarian carcinoma: A Gynecologic Oncology Group study
- (2013) Amanda Nickles Fader et al. GYNECOLOGIC ONCOLOGY
- Staging classification for cancer of the ovary, fallopian tube, and peritoneum
- (2013) Jaime Prat et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling
- (2013) Ali Bashashati et al. JOURNAL OF PATHOLOGY
- Mutational landscape and significance across 12 major cancer types
- (2013) Cyriac Kandoth et al. NATURE
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA
- (2013) Muhammed Murtaza et al. NATURE
- Emerging landscape of oncogenic signatures across human cancers
- (2013) Giovanni Ciriello et al. NATURE GENETICS
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
- (2013) Nicolai Juul Birkbak et al. PLoS One
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
- (2012) J. Murai et al. CANCER RESEARCH
- Mre11-Dependent Degradation of Stalled DNA Replication Forks Is Prevented by BRCA2 and PARP1
- (2012) S. Ying et al. CANCER RESEARCH
- Association Between BRCA1 and BRCA2 Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
- (2012) Kelly L. Bolton JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- BRCA Mutation Frequency and Patterns of Treatment Response in BRCA Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study Group
- (2012) Kathryn Alsop et al. JOURNAL OF CLINICAL ONCOLOGY
- Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies
- (2012) Celeste Leigh Pearce et al. LANCET ONCOLOGY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents
- (2012) G. Zoppoli et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
- (2012) T. Forshew et al. Science Translational Medicine
- Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
- (2012) Janneke E. Jaspers et al. Cancer Discovery
- Mutation and Loss of Expression of ARID1A in Uterine Low-grade Endometrioid Carcinoma
- (2011) Bin Guan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer
- (2011) Shiyu Zhang et al. GYNECOLOGIC ONCOLOGY
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Evolution of platinum resistance in high-grade serous ovarian cancer
- (2011) Susanna L Cooke et al. LANCET ONCOLOGY
- BRCA Mutation Status and Determinant of Outcome in Women with Recurrent Epithelial Ovarian Cancer Treated with Pegylated Liposomal Doxorubicin
- (2011) T. Safra et al. MOLECULAR CANCER THERAPEUTICS
- Integrated genomic analyses of ovarian carcinoma
- (2011) D. Bell et al. NATURE
- Modeling Pharmacodynamic Response to the Poly(ADP-Ribose) Polymerase Inhibitor ABT-888 in Human Peripheral Blood Mononuclear Cells
- (2011) Jiuping Ji et al. PLoS One
- New roles for the major human 3′-5′ exonuclease TREX1 in human disease
- (2010) David Kavanagh et al. CELL CYCLE
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- Gene Expression Profile ofBRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
- (2010) Panagiotis A. Konstantinopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
- (2010) Ahmed Ashour Ahmed et al. JOURNAL OF PATHOLOGY
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
- (2010) M William Audeh et al. LANCET
- ARID1AMutations in Endometriosis-Associated Ovarian Carcinomas
- (2010) Kimberly C. Wiegand et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
- (2010) Ignace Vergote et al. NEW ENGLAND JOURNAL OF MEDICINE
- Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
- (2010) Siân Jones et al. SCIENCE
- Ultrasound-guided tru-cut biopsy of abdominal and pelvic tumors in gynecology
- (2010) M. Zikan et al. ULTRASOUND IN OBSTETRICS & GYNECOLOGY
- Clinicopathological characteristics of mucinous adenocarcinoma of the ovary
- (2009) Muneaki Shimada et al. GYNECOLOGIC ONCOLOGY
- Ovarian carcinoma pathology and genetics: recent advances
- (2009) C. Blake Gilks et al. HUMAN PATHOLOGY
- Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
- (2009) H. Willers et al. MOLECULAR CANCER RESEARCH
- Endometrioid epithelial ovarian cancer
- (2008) Dawn J. Storey et al. CANCER
- Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
- (2008) R. W. Tothill et al. CLINICAL CANCER RESEARCH
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- Image-guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique?
- (2008) Nyree Griffin et al. EUROPEAN RADIOLOGY
- “BRCAness” Syndrome in Ovarian Cancer: A Case-Control Study Describing the Clinical Features and Outcome of Patients With Epithelial Ovarian Cancer Associated WithBRCA1andBRCA2Mutations
- (2008) David S.P. Tan et al. JOURNAL OF CLINICAL ONCOLOGY
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
- Ultrasound-guided tru-cut biopsy in the management of advanced abdomino-pelvic tumors
- (2007) D. FISCHEROVA et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started